ESR1 and metastatic neoplasm: The WHIM16 PDX model also harbors ESR1 amplification (Puenpa et al., 2013), and ESR1 amplification was detected in a primary breast tumor from a patient with ER+ metastatic disease that regressed in response to E2‐based therapy (Kota et al., 2017).